Asset Details
Do you wish to reserve the book?
134 HRT is not detrimental to survival in women diagnosed with stage 1B–2B (FIGO 2009) adenocarcinomas of the cervix aged less than 50
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
134 HRT is not detrimental to survival in women diagnosed with stage 1B–2B (FIGO 2009) adenocarcinomas of the cervix aged less than 50
Do you wish to request the book?
134 HRT is not detrimental to survival in women diagnosed with stage 1B–2B (FIGO 2009) adenocarcinomas of the cervix aged less than 50
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
134 HRT is not detrimental to survival in women diagnosed with stage 1B–2B (FIGO 2009) adenocarcinomas of the cervix aged less than 50
2020
Overview
IntroductionStudies purporting the safety of HRT in cervical cancer have predominantly included patients with squamous disease. Pathological studies have identified increasing estrogen receptor positivity in cervical adenocarcinomas. A recent small case-control study suggested a trend towards reduced survival following HRT use in adenocarcinomas. The objective of this study was to assess if HRT use in patients treated for cervical adenocarcinomas was detrimental to survival.MethodsA retrospective review of all women aged ≤50, with stage 1B-2B cervical adenocarcinoma diagnosed between 1/11/00–24/9/19. Women were categorized as: ovaries conserved (OVCON); or Iatrogenic menopause with (IM-HRT) or without (IM-NOHRT) HRT. HRT use was defined on an intention to treat basis. Statistical analysis was performed using Kaplan-Meier and Cox proportional hazards methods.Results58 women with mean age 38.6±6.5 yrs were included in the study. 25(43.1%) had OVCON, 12(20.7%) had IM-NOHRT and 21(36.2%) had IM-HRT. No menopause-associated deaths occurred. 5-year disease specific survival was 95% in OVCON, 95% in IM-HRT and 64% in IM-NOHRT (p = 0.041 and 0.016 between IM-NOHRT and IM-HRT and OVCON respectively). On multivariate analysis, adjusting for stage, grade, treatment approach and nodal status neither differences remained significant. 5-year progression free survival was 80% in OVCON, 91% in IM-HRT and 66% in IM-NOHRT but this was not statistically significant (p= 0.077).ConclusionsHRT or ovarian conservation does not appear to be detrimental to survival in cervical adenocarcinomas. In this small dataset, there is a trend towards improved survival with HRT. Larger studies are required to substantiate these findings.
Publisher
Elsevier Limited
Subject
